Cingulate Inc. (NASDAQ:CINGW) Sees Large Decrease in Short Interest

Cingulate Inc. (NASDAQ:CINGW) was the recipient of a large drop in short interest during the month of August. As of August 31st, there was short interest totaling 1,533 shares, a drop of 74.1% from the August 15th total of 5,920 shares. Based on an average trading volume of 13,979 shares, the days-to-cover ratio is currently 0.1 days.

Cingulate Stock Performance

NASDAQ:CINGW traded up $0.00 during mid-day trading on Monday, hitting $0.01. 900 shares of the stock traded hands, compared to its average volume of 32,804. Cingulate has a 52 week low of $0.00 and a 52 week high of $0.12. The firm’s 50 day moving average is $0.01 and its two-hundred day moving average is $0.02.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.